Propranolol: An effective immunosuppressive agent in rat heart-lung transplantation

J. R. Womble, Douglas F Larson, Jack G. Copeland, Diane Haddock Russell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have demonstrated that propranolol administration substantially increases allograft survival following rat heart-lung transplantation. Graft rejection appears to result from a T lymphocyte-initiated proliferative response, and propranolol has been shown to inhibit in vitro mitogen-induced T lymphocyte transformation. This is the first report describing the apparent in vivo immunosuppressive activity of propranolol. Clinical transplant rejection is currently treated with relatively toxic drugs including azathioprine and corticosteroids. Propranolol has proved to be free from major toxic effects. We found that low-dose propranolol (1 mg/kg/day) extended heart-lung allograft survival from 6 to more than 12 days when administered as a single agent. Higher propranolol doses (2 and 5 mg/kg/day) also increased graft survival, but to a lesser extent. Further, low-dose propranolol combined with azathioprine (30 mg/kg/day) and methylprednisolone (5 mg/kg/day) resulted in allograft viability in certain rats for longer than 50 days. This 8-fold increase in survival time is particularly remarkable in light of the 75% reduction in concomitant corticosteroid administration in these rats. A comparable decrease in the amount of steroids used to inhibit rejection in clinical transplant patients should result in markedly diminished steroid toxicity. These data suggest that low-dose propranolol is an effective immunosuppressant in the rat heart-lung allograft model, and that utilization of low-dose propranolol could be important in controlling transplant rejection in humans.

Original languageEnglish (US)
Pages (from-to)417-420
Number of pages4
JournalTransplantation
Volume35
Issue number5
StatePublished - 1983

Fingerprint

Heart-Lung Transplantation
Immunosuppressive Agents
Propranolol
Allografts
Graft Rejection
Poisons
Azathioprine
Adrenal Cortex Hormones
Steroids
T-Lymphocytes
Lung
Methylprednisolone
Graft Survival
Lymphocyte Activation
Mitogens
Transplants

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Womble, J. R., Larson, D. F., Copeland, J. G., & Russell, D. H. (1983). Propranolol: An effective immunosuppressive agent in rat heart-lung transplantation. Transplantation, 35(5), 417-420.

Propranolol : An effective immunosuppressive agent in rat heart-lung transplantation. / Womble, J. R.; Larson, Douglas F; Copeland, Jack G.; Russell, Diane Haddock.

In: Transplantation, Vol. 35, No. 5, 1983, p. 417-420.

Research output: Contribution to journalArticle

Womble, JR, Larson, DF, Copeland, JG & Russell, DH 1983, 'Propranolol: An effective immunosuppressive agent in rat heart-lung transplantation', Transplantation, vol. 35, no. 5, pp. 417-420.
Womble, J. R. ; Larson, Douglas F ; Copeland, Jack G. ; Russell, Diane Haddock. / Propranolol : An effective immunosuppressive agent in rat heart-lung transplantation. In: Transplantation. 1983 ; Vol. 35, No. 5. pp. 417-420.
@article{c7bf997ba2b741898cc9a09720a1d497,
title = "Propranolol: An effective immunosuppressive agent in rat heart-lung transplantation",
abstract = "We have demonstrated that propranolol administration substantially increases allograft survival following rat heart-lung transplantation. Graft rejection appears to result from a T lymphocyte-initiated proliferative response, and propranolol has been shown to inhibit in vitro mitogen-induced T lymphocyte transformation. This is the first report describing the apparent in vivo immunosuppressive activity of propranolol. Clinical transplant rejection is currently treated with relatively toxic drugs including azathioprine and corticosteroids. Propranolol has proved to be free from major toxic effects. We found that low-dose propranolol (1 mg/kg/day) extended heart-lung allograft survival from 6 to more than 12 days when administered as a single agent. Higher propranolol doses (2 and 5 mg/kg/day) also increased graft survival, but to a lesser extent. Further, low-dose propranolol combined with azathioprine (30 mg/kg/day) and methylprednisolone (5 mg/kg/day) resulted in allograft viability in certain rats for longer than 50 days. This 8-fold increase in survival time is particularly remarkable in light of the 75{\%} reduction in concomitant corticosteroid administration in these rats. A comparable decrease in the amount of steroids used to inhibit rejection in clinical transplant patients should result in markedly diminished steroid toxicity. These data suggest that low-dose propranolol is an effective immunosuppressant in the rat heart-lung allograft model, and that utilization of low-dose propranolol could be important in controlling transplant rejection in humans.",
author = "Womble, {J. R.} and Larson, {Douglas F} and Copeland, {Jack G.} and Russell, {Diane Haddock}",
year = "1983",
language = "English (US)",
volume = "35",
pages = "417--420",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Propranolol

T2 - An effective immunosuppressive agent in rat heart-lung transplantation

AU - Womble, J. R.

AU - Larson, Douglas F

AU - Copeland, Jack G.

AU - Russell, Diane Haddock

PY - 1983

Y1 - 1983

N2 - We have demonstrated that propranolol administration substantially increases allograft survival following rat heart-lung transplantation. Graft rejection appears to result from a T lymphocyte-initiated proliferative response, and propranolol has been shown to inhibit in vitro mitogen-induced T lymphocyte transformation. This is the first report describing the apparent in vivo immunosuppressive activity of propranolol. Clinical transplant rejection is currently treated with relatively toxic drugs including azathioprine and corticosteroids. Propranolol has proved to be free from major toxic effects. We found that low-dose propranolol (1 mg/kg/day) extended heart-lung allograft survival from 6 to more than 12 days when administered as a single agent. Higher propranolol doses (2 and 5 mg/kg/day) also increased graft survival, but to a lesser extent. Further, low-dose propranolol combined with azathioprine (30 mg/kg/day) and methylprednisolone (5 mg/kg/day) resulted in allograft viability in certain rats for longer than 50 days. This 8-fold increase in survival time is particularly remarkable in light of the 75% reduction in concomitant corticosteroid administration in these rats. A comparable decrease in the amount of steroids used to inhibit rejection in clinical transplant patients should result in markedly diminished steroid toxicity. These data suggest that low-dose propranolol is an effective immunosuppressant in the rat heart-lung allograft model, and that utilization of low-dose propranolol could be important in controlling transplant rejection in humans.

AB - We have demonstrated that propranolol administration substantially increases allograft survival following rat heart-lung transplantation. Graft rejection appears to result from a T lymphocyte-initiated proliferative response, and propranolol has been shown to inhibit in vitro mitogen-induced T lymphocyte transformation. This is the first report describing the apparent in vivo immunosuppressive activity of propranolol. Clinical transplant rejection is currently treated with relatively toxic drugs including azathioprine and corticosteroids. Propranolol has proved to be free from major toxic effects. We found that low-dose propranolol (1 mg/kg/day) extended heart-lung allograft survival from 6 to more than 12 days when administered as a single agent. Higher propranolol doses (2 and 5 mg/kg/day) also increased graft survival, but to a lesser extent. Further, low-dose propranolol combined with azathioprine (30 mg/kg/day) and methylprednisolone (5 mg/kg/day) resulted in allograft viability in certain rats for longer than 50 days. This 8-fold increase in survival time is particularly remarkable in light of the 75% reduction in concomitant corticosteroid administration in these rats. A comparable decrease in the amount of steroids used to inhibit rejection in clinical transplant patients should result in markedly diminished steroid toxicity. These data suggest that low-dose propranolol is an effective immunosuppressant in the rat heart-lung allograft model, and that utilization of low-dose propranolol could be important in controlling transplant rejection in humans.

UR - http://www.scopus.com/inward/record.url?scp=0020574538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020574538&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020574538

VL - 35

SP - 417

EP - 420

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -